





{"id":136,"date":"2017-07-10T12:33:27","date_gmt":"2017-07-10T10:33:27","guid":{"rendered":"https:\/\/www.degro.org\/ag-stereotaxie\/?page_id=136"},"modified":"2023-10-11T14:03:27","modified_gmt":"2023-10-11T12:03:27","slug":"medical-physics-projects","status":"publish","type":"page","link":"https:\/\/www.degro.org\/ag-stereotaxie\/projekte\/aktuelle-projekte\/medical-physics-projects\/","title":{"rendered":"Medical physics projects"},"content":{"rendered":"<div id=\"pl-136\"  class=\"panel-layout\" ><div id=\"pg-136-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-136-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-136-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2>Planning benchmark study for SBRT for lung, liver and pancreas tumors<\/h2>\n<hr \/>\n<h4><strong>Study PI:<\/strong><\/h4>\n<p>Christos Moustakis<br \/>Uni-Klinikum M\u00fcnster<br \/><a href=\"mailto:Christos.Moustakis@ukmuenster.de\">Christos.Moustakis@ukmuenster.de<\/a><\/p>\n<p>Stephanie Tanadini-Lang, Lotte Wilke<br \/>University Hospital Z\u00fcrich<br \/><a href=\"mailto:stephanie.tanadini-lang@usz.ch\">stephanie.tanadini-lang@usz.ch<\/a><\/p>\n<h4><strong>Study design:<\/strong><\/h4>\n<p>\u25cf multi-center, multi-platform bench mark study<\/p>\n<h4><strong>Study objectives:<\/strong><\/h4>\n<ul>\n<li>To harmonize treatment planning reporting and quality for lung SBRT based on the published guidelines of the DEGRO AG Stereotaxie<\/li>\n<li>To harmonize treatment planning reporting and quality for liver SBRT based on the published guidelines of the DEGRO AG Stereotaxie<\/li>\n<li>To harmonize treatment planning reporting and quality for pancreas SBRT based on the published guidelines of the DEGRO AG Stereotaxie<\/li>\n<li>To harmonize treatment planning based on \u00a0a mean ITV\/GTV dose prescription<\/li>\n<\/ul>\n<h4><strong>Project status:<\/strong><\/h4>\n<p>\u25cf Data collection completed<br \/>\u25cf 3 manuscripts published, 1 manuscript in preparation<\/p>\n<h4><strong>Major findings and results:<\/strong><\/h4>\n<p>Moustakis C, Blanck O, Chan MKH, et al.<strong> Planning Benchmark Study for Stereotactic Body Radiation Therapy of Liver Metastases: Results of the DEGRO\/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. <\/strong>Int J Radiat Oncol Biol Phys. 2022; 113(1):214-227. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35074434\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35074434\/<\/a><\/p>\n<ul>\n<li>3 typical Liver SBRT cases<\/li>\n<li>35 participating institutions and 132 generated plans<\/li>\n<li>SBRT treatment planning with 3\u00d720Gy prescribed to the mean GTV dose<\/li>\n<li>Further objectives and constraints for GTV, PTV and OAR were provided<\/li>\n<li>Constraints could not always be fulfilled and trade-offs significantly varied between institutions<\/li>\n<li>Five different methods of prescription were compared for a total of 660 plans<\/li>\n<li>The mean GTV dose prescription resulted in the least difference for all parameters evaluated<\/li>\n<\/ul>\n<p>Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, et al. <strong>Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28567503\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28567503\/<\/a><\/p>\n<ul>\n<li>3 typical cases, 22 institutions, 87 plans, 3 x 15 Gy @ 65% isodose<\/li>\n<li>PTV dose coverage and simultaneously OARs doses were kept within the clinical limits published in the DEGRO AG guidelines and homogenization of SBRT practice was possible based on the guidelines<\/li>\n<li>However, detailed treatment plan characteristics still varied between techniques and institutions and further standardization is warranted, mainly in respect to the mean PTV and GTV dose.<\/li>\n<li>Regardless, the ALARA principle should always be applied to optimize treatment planning<\/li>\n<li>In summary, all treatment techniques, with all their known advantages and disadvantages, are well suited for SBRT of early stage NSCLC according to the DEGRO AG guidelines.<\/li>\n<\/ul>\n<p>Wilke L, Moustakis C, Blanck O, et al. <strong>Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose<\/strong>. Strahlenther Onkol. 2021; 197(9):836-846. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34196725\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34196725\/<\/a><\/p>\n<ul>\n<li>2 typical lung SBRT cases, same ones as in the last study<\/li>\n<li>27 participating institutions, 57 plans<\/li>\n<li>SBRT treatment planning with 3x21.5Gy on the mean ITV dose<\/li>\n<li>A set on further constraints on PTV, ITV and OAR was provided<\/li>\n<li>Constraints could mostly be fulfilled<\/li>\n<li>Mean PTV dose differs only by maximally 1.5Gy between the techniques (compared to more than 5 Gy in previous study)<\/li>\n<li>In summary, difference between different treatment techniques could be homogenized by prescribing on the mean ITV dose<\/li>\n<li>Data acquisition finished, manuscript in preparation<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Planning benchmark study for SBRT for lung, liver and pancreas tumorsStudy PI:Christos MoustakisUni-Klinikum M\u00fcnsterChristos.Moustakis@ukmuenster.deStephanie Tanadini-Lang, Lotte WilkeUniversity Hospital Z\u00fcrichstephanie.tanadini-lang@usz.chStudy design:\u25cf multi-center, multi-platform bench mark studyStudy objectives:To harmonize treatment planning reporting and quality for lung SBRT based on the published guidelines &hellip; <\/p>\n","protected":false},"author":8,"featured_media":0,"parent":77,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-136","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/comments?post=136"}],"version-history":[{"count":14,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/136\/revisions"}],"predecessor-version":[{"id":973,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/136\/revisions\/973"}],"up":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/77"}],"wp:attachment":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/media?parent=136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}